[144] Royalty Pharma plc SEC Filing
Rhea-AI Filing Summary
RPRX submitted a Form 144 reporting a proposed sale of 100,462 shares of Common Stock acquired on 06/20/2020.
The filing lists the broker Goldman Sachs & Co. LLC and records multiple sales by affiliated entities over the prior three months, including transactions dated 01/07/2026, 01/21/2026, and 03/04/2026 with share amounts and gross proceeds documented in the filing.
Positive
- None.
Negative
- None.
Insights
Form 144 notifies the market of an intended resale of restricted or control stock.
The filing identifies 100,462 shares of Common Stock acquired 06/20/2020 and lists Goldman Sachs & Co. LLC as the broker. That quantity is presented as the securities to be sold in this notice.
Recent executed transactions by affiliated holders are enumerated with dates and gross proceeds, which investors can use as a trading history reference; subsequent filings will report completed dispositions.
The filing shows active resale activity by related entities over the past three months.
The excerpt records multiple sales: for example, GWL 2013 NG LLC sold 123,965 shares on 01/07/2026 and 123,965 shares on 01/21/2026, with gross proceeds listed. Another entry shows George Lloyd IRA sold 136,980 shares on 03/04/2026 for a stated dollar amount.
These executed sales provide context for the Form 144 notice; the filing itself documents intent to resell 100,462 shares acquired in 2020.
FAQ
What does RPRX's Form 144 report?
Who appears as broker for the RPRX sale in the Form 144?
Does the excerpt show prior resale activity for RPRX shares?
When were the securities to be sold originally acquired?